Assessing Whether Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Is Over- Or Undervalued


    The Vanguard Group, Inc. has recently announced that it has increased stake in Iovance Biotherapeutics Inc. (NASDAQ:IOVA) by 11.47%. After grabbing 12.03 million shares, the institutional investor is now in possession of 1.24 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.48% having worth around $349.58 million. Moreover, Perceptive Advisors LLC increased its share by 0.14 million to have a control over 11.81 million shares. And Avoro Capital Advisor LLC raised its holdings to 1.35 million shares by acquiring 10.36 million shares or 8.17% of the stake.

    Iovance Biotherapeutics Inc. (IOVA) concluded trading on 08/27/20 at a closing price of $29.22, with 1.44 million shares of worth about $41.96 million changed hands on the day. Weekly performance of the stock remained positive as price took a surge of 0.90% during that period and on Thursday the price saw a gain of about 4.43%. Currently the company’s common shares owned by public are about 133.16M shares, out of which, 101.92M shares are available for trading.

    Analysts also issued an outlook of 1.70 for the Iovance Biotherapeutics Inc. stock for next 12 months.

    According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

    ARK Innovation ETF, Vanguard Total Stock Market Index, and Vanguard Small Cap Index Fund are the top 3 mutual funds which are holding stakes in Iovance Biotherapeutics Inc. ARK Innovation ETF is currently holding 4.11 million shares of worth totaling $119.58 million. The company recently came buying 43945.0 shares which brought its stake up to 3.24% of the company’s outstanding shares. Vanguard Total Stock Market Index sold 431.0 shares, after which its hold over company’s outstanding shares shrunk to 2.92%, leaving 3.7 million shares with the mutual fund that have a worth of about $107.51 million. Vanguard Small Cap Index Fund, after selling 3.22 million shares, have now control over 2.54% of the stake in the company. It holds 20388.0 shares of worth $93.52 million.

    Iovance Biotherapeutics Inc. (NASDAQ: IOVA) started trading at $28.20, above $0.22 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $29.22, or with a gain of 4.43%. Stock saw a price change of 0.90% in past 5 days and over the past one month there was a price change of 1.99%. Year-to-date (YTD), IOVA shares are showing a performance of 5.56% which increased to 44.08% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $17.67 but also hit the highest price of $41.49 during that period. While comparing its average daily trading volume of 1.79 million shares, we see that about 1.44 million changed hands on the day. The stock is currently trading 0.23% above its 20-day simple moving average (SMA20), while that difference is up 0.06% for SMA50 and it goes to 1.40% higher than SMA200.

    The Vanguard Group, Inc. acquired 12.03 million shares of Iovance Biotherapeutics Inc. having value of about $349.58 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 1.24 million shares in the company valued at close to $36165009.6, or have control over 11.47% stake in the company. Holding of mutual funds in the company is about 51.49% while other institutional holders and individual stake holders have control over 61.21% and 0.74% of the stake respectively.

    The stock has a current market capitalization of $4.24B and its 3Y-monthly beta is at 0.99. It has posted earnings per share of -$1.93 in the same period. It has Quick Ratio of 14.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IOVA, volatility over the week remained 4.07% while standing at 4.40% over the month.

    Analysts are in expectations that Iovance Biotherapeutics Inc. (IOVA) stock would likely to be making an EPS of -$0.46 in the current quarter, while forecast for next quarter ESPS is -$0.48 and it is -$2.02 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.54 which is -$0.39 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.4 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -25.10% while it is estimated to decrease by 0.00% in next year.

    Analysts at 12 brokerage firms have issued recommendations for the Iovance Biotherapeutics Inc. (IOVA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 12 Wall Street analysts, 11 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

    Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on April 22, 2020 offering a Buy rating for the stock and assigned a target price of $61 to it. Coverage by Barclays stated Iovance Biotherapeutics Inc. (IOVA) stock as an Overweight in their note to investors on March 04, 2020, suggesting a price target of $45 for the stock. On February 26, 2020, Oppenheimer Reiterated their recommendations, while on February 26, 2020, H.C. Wainwright Reiterated their ratings for the stock with a price target of $36. Stock get a Mkt outperform rating from JMP Securities on December 18, 2019.


    Please enter your comment!
    Please enter your name here